Innoviva (INVA) Expected to Announce Earnings on Wednesday

Innoviva (NASDAQ:INVA) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.34 per share and revenue of $102.6240 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Innoviva Stock Up 0.1%

Innoviva stock opened at $23.41 on Tuesday. The firm has a 50 day simple moving average of $20.59 and a 200 day simple moving average of $19.97. The company has a current ratio of 14.12, a quick ratio of 13.33 and a debt-to-equity ratio of 0.25. Innoviva has a 1-year low of $16.52 and a 1-year high of $24.01. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of 17.09 and a beta of 0.44.

Institutional Trading of Innoviva

Large investors have recently modified their holdings of the business. Royal Bank of Canada grew its holdings in shares of Innoviva by 81.1% during the first quarter. Royal Bank of Canada now owns 21,530 shares of the biotechnology company’s stock worth $389,000 after purchasing an additional 9,639 shares in the last quarter. AQR Capital Management LLC lifted its position in Innoviva by 17.8% during the first quarter. AQR Capital Management LLC now owns 167,456 shares of the biotechnology company’s stock valued at $3,036,000 after purchasing an additional 25,317 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Innoviva by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,882 shares of the biotechnology company’s stock worth $596,000 after buying an additional 1,392 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Innoviva in the 1st quarter worth $243,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Innoviva by 21.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 171,116 shares of the biotechnology company’s stock valued at $3,102,000 after buying an additional 30,792 shares in the last quarter. Institutional investors own 99.12% of the company’s stock.

Analyst Ratings Changes

INVA has been the subject of a number of analyst reports. BTIG Research started coverage on Innoviva in a report on Tuesday, February 17th. They issued a “buy” rating and a $35.00 price target for the company. HC Wainwright raised their target price on Innoviva from $45.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Cantor Fitzgerald upped their price target on Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Zacks Research downgraded shares of Innoviva from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Innoviva in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.17.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.